Sambasivan Khrishanthne, Mahmoud Sarah, Kokache Arwa, Seckl Michael, Savage Philip
Department of Medical Oncology, Charing Cross Hospital, London, UK.
J Oncol Pharm Pract. 2014 Apr;20(2):158-60. doi: 10.1177/1078155213488015. Epub 2013 Jun 4.
Etoposide phosphate is a prodrug of intravenous etoposide recommended for use in patients with demonstrated allergy to etoposide. We have previously published a case series comprising six patients who were successfully treated with etoposide phosphate following preceding etoposide hypersensitivity. In this new paper we now present the cases of two patients who had allergic reactions to both etoposide and etoposide phosphate. As such, we suggest that whilst most patients with etoposide hypersensitivity can safely be treated with etoposide phosphate, a small number are at risk of an additional allergic reaction to etoposide phosphate. Patients being treated for the first time with etoposide phosphate after etoposide allergy should receive their first dose under medical supervision.